021-51111890
购物车（）
sales@molnova.cn
Codrituzumab
CAS No. 1365267-33-9
Codrituzumab ( —— )
产品货号. M36896 CAS No. 1365267-33-9
Codrituzumab 是一种靶向 GPC3 (glypican-3) 的单克隆抗体。GPC3 是一种表达于肝细胞癌 (HCC) 细胞表面的癌胚蛋白。Codrituzumab 诱导抗体依赖性细胞毒性 (ADCC) 并抑制肿瘤生长。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥1758 | 有现货 |
|
| 5MG | ￥2993 | 有现货 |
|
| 10MG | ￥4294 | 有现货 |
|
| 25MG | ￥6501 | 有现货 |
|
| 50MG | ￥8761 | 有现货 |
|
| 100MG | ￥11430 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Codrituzumab
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Codrituzumab 是一种靶向 GPC3 (glypican-3) 的单克隆抗体。GPC3 是一种表达于肝细胞癌 (HCC) 细胞表面的癌胚蛋白。Codrituzumab 诱导抗体依赖性细胞毒性 (ADCC) 并抑制肿瘤生长。
-
产品描述Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth.
-
体外实验——
-
体内实验——
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域——
-
适应症——
化学信息
-
CAS Number1365267-33-9
-
分子量
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Mika Endo, et al. Abstract 2747: Anti-glypican-3 monoclonal antibody (codrituzumab/GC33/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1 monoclonal antibody promotes antitumor effects. Cancer Res (2018) 78 (13_Supplement): 2747.
产品手册
关联产品
-
30-Hydroxygambogic a...
30-Hydroxygambogic acid exhibits significant cytotoxicities against the human leukemia K562/S and the corresponding doxorubicin-resistant K562/R cell lines.
-
Cannabidivarin
Cannabidivarin 是 GABAA 受体 γ 2 亚基的有效抑制剂。它可能作为一种新药，对儿童失神癫痫有一定的控制作用。
-
ASC-JM-17
ASC-JM-17 is an activator of both Nrf1 and Nrf2 proteins. ASC-JM17 acts on Nrf1, Nrf2 and Hsf1 to increase the expression of proteasome subunits, antioxidant enzymes and molecular chaperones. ASC-JM17 ameliorates toxicity of the mutant androgen receptor (AR) responsible for SBMA in cell, fly and mouse models. Knockdown of the Drosophila Nrf1 and Nrf2 ortholog cap ‘n’ collar isoform-C, but not Hsf1, blocks the protective effect of ASC-JM17 on mutant AR-induced eye degeneration in flies.
